申请人:Ono Pharmaceutical Co., Ltd.
公开号:US07713998B2
公开(公告)日:2010-05-11
The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I):
wherein all the symbols are as defined in the description, or its salt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof.
The compound of the general formula (I) has a p38 MAP kinase inhibitory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.
本发明涉及一种具有p38 MAP激酶抑制活性的化合物,可用作药物,其通式表示为(I):其中所有符号在说明中定义,或其盐,N-氧化物或溶剂化物,或其前药。此外,还提供了制备该化合物的方法和用途。通式(I)的化合物具有p38 MAP激酶抑制活性,并且可用于预防和/或治疗细胞因子异常产生的疾病,例如炎性细胞因子或趋化因子,或其过度反应会导致病理状况的疾病,即细胞因子介导的疾病,例如炎症性疾病、呼吸系统疾病、循环系统疾病、中枢神经系统疾病等。